OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a biotechnology company focused on antibody discovery technologies, having completed its business combination with Avista Public Acquisition Corp. II in October 2022. The SPAC, sponsored by Avista Capital Partners, priced its initial public offering in 2021 with a focus on the life sciences sector. OmniAb was spun off from Ligand Pharmaceuticals as part of the de-SPAC transaction, offering partners access to its proprietary transgenic animal platforms for generating therapeutic antibody candidates. The company filed this Form 8-K with the SEC on June 26, 2023, reflecting its ongoing reporting obligations as a public company. Sign up for full data on SpacDesk to track OmniAb's complete filing history and post-merger activity.